Results 51 to 60 of about 18,139 (185)
Harm Reduction Journal, 2012 Background Respiratory depression, a potentially fatal side-effect of opioid-overdose, may be reversed by timely administration of an opioid antagonist, such as naloxone or naltrexone.
Goli Veeraindar +5 more
doaj +1 more source
Comparison of Disulfiram and Naltrexone in Cases of Alcohol Dependence Syndrome
Journal of Nepal Health Research Council, 2020 Background: Relapse prevention in alcoholism is recognised as an important component of management. Use of pharmacotherapies to prevent relapse in combination to psychological intervention is emerging.
Sandarba Adhikari +5 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller +3 more
wiley +1 more source
Journal of Pharmacological Sciences, 2005 Heat stroke is characterized by hyperthermia, arterial hypotension, decreased baroreflex sensitivity, and increased serum levels of β-endorphin. Whereas naltrexone may have therapeutic potential in heat stroke, the underlying mechanism remains unclear ...
Yi-Ping Huang +3 more
doaj +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
British Journal of Pharmacology, EarlyView.Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Opioids in breast cancer: Between analgesia and modulation of tumour progression
British Journal of Pharmacology, EarlyView.Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun +2 more
wiley +1 more source
Secondary analysis of a combined harm-reduction treatment and extended-release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth. [PDF]
AddictionAbstract Background and Aims In a prior randomized clinical trial (RCT), combined pharmacobehavioral harm‐reduction treatment improved alcohol outcomes and physical health‐related quality of life (PH‐QoL). In this secondary analysis, we tested race, ethnicity and sex assigned at birth as predictors and moderators of these effects.
Goldstein SC +4 more
europepmc +2 more sources